The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
May 14th 2024
Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Diabetes Dialogue: SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023
November 11th 2023In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
Semaglutide 2.4 mg (Wegovy) Reduces Cardiovascular Risk in Overweight/Obesity with CVD
November 11th 2023Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.
Kidney Week 2023: Evolving Recognition of Cardiovascular, Kidney, and Metabolic Disease
November 7th 2023Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.
Mitigating Cardiovascular Risk In Obesity
October 23rd 2023Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.
Determining Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure, with Ankeet Bhatt, MD, MBA
October 10th 2023Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.
REBALANCE-HF: Greater Splanchnic Nerve Ablation Could Prove Beneficial in HFpEF
October 8th 2023The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.